Markets
← Back to Stocks
CRL
CHARLES RIVER LABORATORIES
Health Care · Life Sciences Tools & Services
$152.92
-2.73%
Vol: 0.0M
Araverus Market Read
Thursday, March 19, 2026
Charles River Laboratories beats Q4 earnings but slides 2.24% as market scrutinizes valuation despite buy consensus.
Charles River declined 2.24% in 24-hour trading despite Q4 EPS beat ($2.39 vs. $2.34 consensus) and resilience in healthcare sector. The stock rose 0.19% despite broader 1.45% sector decline, suggesting relative strength. Analysts maintain Buy rating with 12-month target of $205.27 (29.48% upside from $154.01 USD). Next earnings report due May 7, 2026.
Price 50d 200d
Previous Market Reads
2 of 2 days↓
Sector Peers
| Company | Price | Day | 1M | Fwd P/E | Beta | Mkt Cap |
|---|---|---|---|---|---|---|
| LLYELI | $916.83 | -0.13% | -11.4% | 21.8x | 0.43 | $821.2B |
| JNJJOHNSON | $237.56 | +0.16% | -1.8% | 18.9x | 0.33 | $572.6B |
| ABBVABBVIE | $206.31 | -0.97% | -11.4% | 12.8x | 0.33 | $364.6B |
| MRKMERCK | $114.17 | -0.29% | -5.4% | 11.7x | 0.26 | $282.3B |
| UNHUNITEDHEALTH | $280.37 | -1.29% | -2.2% | 14.1x | 0.38 | $254.5B |
| AMGNAMGEN | $349.90 | -0.42% | -6.3% | 15.0x | 0.42 | $188.6B |
| ABTABBOTT | $107.19 | -1.12% | -4.5% | 17.2x | 0.74 | $186.3B |
| GILDGILEAD | $141.06 | -0.17% | -8.6% | 14.7x | 0.37 | $175.2B |
| TMOTHERMO | $470.21 | +1.18% | -6.2% | 17.5x | 0.97 | $174.7B |
Fundamentals
Market Cap$7.5B
P/E (TTM)—
Forward P/E12.5
Beta1.65
Div Yield—
Prev Close$157.21
RSI (14-Day)
29Oversold
0305070100
52-Week Range
$91.86$152.92$228.88
From High-33.2%
From Low+66.5%
Moving Averages
50d SMA
$187.80-18.6%
200d SMA
$172.99-11.6%
Price below 200d MA — bearish structure.
Returns
1W
+0.2%
1M
-3.2%
3M
-21.7%
6M
+0.1%
1Y
-13.6%
YTD
-24.4%
Volume
Today33K
20d Avg986K
Ratio0.03x